Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
JCI Insight ; 6(15)2021 08 09.
Article in English | MEDLINE | ID: covidwho-1286768

ABSTRACT

Immune dysregulation is characteristic of the more severe stages of SARS-CoV-2 infection. Understanding the mechanisms by which the immune system contributes to COVID-19 severity may open new avenues to treatment. Here, we report that elevated IL-13 was associated with the need for mechanical ventilation in 2 independent patient cohorts. In addition, patients who acquired COVID-19 while prescribed Dupilumab, a mAb that blocks IL-13 and IL-4 signaling, had less severe disease. In SARS-CoV-2-infected mice, IL-13 neutralization reduced death and disease severity without affecting viral load, demonstrating an immunopathogenic role for this cytokine. Following anti-IL-13 treatment in infected mice, hyaluronan synthase 1 (Has1) was the most downregulated gene, and accumulation of the hyaluronan (HA) polysaccharide was decreased in the lung. In patients with COVID-19, HA was increased in the lungs and plasma. Blockade of the HA receptor, CD44, reduced mortality in infected mice, supporting the importance of HA as a pathogenic mediator. Finally, HA was directly induced in the lungs of mice by administration of IL-13, indicating a new role for IL-13 in lung disease. Understanding the role of IL-13 and HA has important implications for therapy of COVID-19 and, potentially, other pulmonary diseases. IL-13 levels were elevated in patients with severe COVID-19. In a mouse model of the disease, IL-13 neutralization reduced the disease and decreased lung HA deposition. Administration of IL-13-induced HA in the lung. Blockade of the HA receptor CD44 prevented mortality, highlighting a potentially novel mechanism for IL-13-mediated HA synthesis in pulmonary pathology.


Subject(s)
COVID-19/immunology , Interleukin-13/immunology , SARS-CoV-2/immunology , Animals , COVID-19/blood , COVID-19/pathology , COVID-19/therapy , Disease Models, Animal , Disease Progression , Female , Humans , Interleukin-13/blood , Lung/immunology , Lung/pathology , Male , Mice , Mice, Inbred C57BL , Severity of Illness Index
2.
J Histochem Cytochem ; 68(12): 907-927, 2020 12.
Article in English | MEDLINE | ID: covidwho-637123

ABSTRACT

Inter-α-trypsin inhibitor (IαI) family members are ancient and unique molecules that have evolved over several hundred million years of vertebrate evolution. IαI is a complex containing the proteoglycan bikunin to which heavy chain proteins are covalently attached to the chondroitin sulfate chain. Besides its matrix protective activity through protease inhibitory action, IαI family members interact with extracellular matrix molecules and most notably hyaluronan, inhibit complement, and provide cell regulatory functions. Recent evidence for the diverse roles of the IαI family in both biology and pathology is reviewed and gives insight into their pivotal roles in tissue homeostasis. In addition, the clinical uses of these molecules are explored, such as in the treatment of inflammatory conditions including sepsis and Kawasaki disease, which has recently been associated with severe acute respiratory syndrome coronavirus 2 infection in children.


Subject(s)
Alpha-Globulins/metabolism , Alpha-Globulins/analysis , Animals , Arthritis/metabolism , Arthritis/pathology , Asthma/metabolism , Asthma/pathology , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Fibrosis , Humans , Hyaluronic Acid/metabolism , Inflammation/metabolism , Inflammation/pathology , Sepsis/metabolism , Sepsis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL